Restricted accessResearch articleFirst published online 2021-03
Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress
Empagliflozin (EMPA) demonstrates cardioprotective effects on diabetic myocardium but its infarct-sparing effects in normoglycemia remain unspecified. We investigated the acute and chronic effect of EMPA on infarct size after ischemia-reperfusion (I/R) injury and the mechanisms of cardioprotection in nondiabetic mice.
Results:
Chronic oral administration of EMPA (6 weeks) reduced myocardial infarct size after 30 min/2 h I/R (26.5% ± 3.9% vs 45.8% ± 3.3% in the control group, p < 0.01). Body weight, blood pressure, glucose levels, and cardiac function remained unchanged between groups. Acute administration of EMPA 24 or 4 h before I/R did not affect infarct size. Chronic EMPA treatment led to a significant reduction of oxidative stress biomarkers. STAT-3 (signal transducer and activator of transcription 3) was activated by Y(705) phosphorylation at the 10th minute of R, but it remained unchanged at 2 h of R and in the acute administration protocols. Proteomic analysis was employed to investigate signaling intermediates and revealed that chronic EMPA treatment regulates several pathways at reperfusion, including oxidative stress and integrin-related proteins that were further evaluated. Superoxide dismutase and vascular endothelial growth factor were increased throughout reperfusion. EMPA pretreatment (24 h) increased the viability of human microvascular endothelial cells in normoxia and on 3 h hypoxia/1 h reoxygenation and reduced reactive oxygen species production. In EMPA-treated murine hearts, CD31-/VEGFR2-positive endothelial cells and the pSTAT-3(Y705) signal derived from endothelial cells were boosted at early reperfusion.
Innovation:
Chronic EMPA administration reduces infarct size in healthy mice via the STAT-3 pathway and increases the survival of endothelial cells.
Conclusion:
Chronic but not acute administration of EMPA reduces infarct size through STAT-3 activation independently of diabetes mellitus.
Get full access to this article
View all access options for this article.
References
1.
AbdurrachimD, MandersE, NicolayK, MayouxE, and PrompersJJ. Single dose of empagliflozin increases in vivo cardiac energy status in diabetic db/db mice. Cardiovasc Res, 114: 1843–1844, 2018.
2.
AbhinandCS, RajuR, SoumyaSJ, AryaPS, and SudhakaranPR. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal, 10: 347–354, 2016.
3.
AndreadouI, BellRM, BøtkerHE, and ZuurbierCJ. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta, 1866: 165770, 2020.
4.
AndreadouI, EfentakisP, BalafasE, TogliattoG, DavosCH, VarelaA, DimitriouCA, NikolaouP-E, MaratouE, LambadiariV, IkonomidisI, KostomitsopoulosN, BrizziMF, DimitriadisG, and IliodromitisEK. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol, 8: 1077, 2017.
5.
AndreadouI, FarmakisD, ProkovasE, SigalaF, ZogaA, SpyridakiK, PapaloisA, PapapetropoulosA, Anastasiou-NanaM, KremastinosDT, and IliodromitisEK. Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res, 94: 501–509, 2012.
6.
BaartscheerA, SchumacherCA, WüstRCI, FioletJWT, StienenGJM, CoronelR, and ZuurbierCJ. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+>/H+ exchanger in rats and rabbits. Diabetologia, 60: 568–573, 2017.
7.
BaderAM, BrodaracA, KloseK, BiebackK, ChoiY-H, KurtzA, and StammC. Mechanisms of paracrine cardioprotection by cord blood mesenchymal stromal cells. Eur J Cardiothorac Surg, 45: 983–992, 2014.
8.
BarlowHR and CleaverO. Building blood vessels-one Rho GTPase at a time. Cells, 8: E545, 2019.
BoenglerK, BuechertA, HeinenY, RoeskesC, Hilfiker-KleinerD, HeuschG, and SchulzR. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res, 102: 131–135, 2008.
11.
BoenglerK, Hilfiker-KleinerD, HeuschG, and SchulzR. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol, 105: 771–785, 2010.
12.
BolliR, DawnB, and XuanY-T. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med, 13: 72–79, 2003.
13.
BøtkerHE, HausenloyD, AndreadouI, AntonucciS, BoenglerK, DavidsonSM, DeshwalS, DevauxY, Di LisaF, Di SanteM, EfentakisP, FemminòS, García-DoradoD, GiriczZ, IbanezB, IliodromitisE, KaludercicN, KleinbongardP, NeuhäuserM, OvizeM, PagliaroP, Rahbek-SchmidtM, Ruiz-MeanaM, SchlüterK-D, SchulzR, SkyschallyA, WilderC, YellonDM, FerdinandyP, and HeuschG. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol, 113: 39, 2018.
14.
ChenZ and HanZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev, 28: 185–200, 2008.
15.
ChuC, LuY-P, YinL, and HocherB. The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press Res, 44: 149–157, 2019.
16.
ConnellyKA, ZhangY, VisramA, AdvaniA, BatchuSN, DesjardinsJ-F, ThaiK, and GilbertRE. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. J Am Coll Cardiol Basic Trans Sci, 4: 27–37, 2019.
17.
DavidsonSM, FerdinandyP, AndreadouI, BøtkerHE, HeuschG, IbáñezB, OvizeM, SchulzR, YellonDM, HausenloyDJ, Garcia-Dorado D; Action (CA16225) on Behalf of theEUCC. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol, 73: 89–99, 2019.
18.
DhallaNS, ElmoselhiAB, HataT, and MakinoN. Status of myocardial antioxidants in ischemia–reperfusion injury. Cardiovasc Res, 47: 446–456, 2000.
19.
EfentakisP, AndreadouI, BibliS-I, VasileiouS, DagresN, ZogaA, LougiakisN, KremastinosDT, and IliodromitisEK. Ranolazine triggers pharmacological preconditioning and postconditioning in anesthetized rabbits through activation of RISK pathway. Eur J Pharmacol, 789: 431–438, 2016.
20.
EfentakisP, KremastiotisG, VarelaA, NikolaouP-E, PapanagnouE-D, DavosCH, TsoumaniM, AgrogiannisG, KonstantinidouA, KastritisE, KanakiZ, IliodromitisEK, KlinakisA, DimopoulosMA, TrougakosIP, AndreadouI, and TerposE. Molecular mechanisms of Carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of Metformin. Blood, 133: 710–723, 2019.
21.
EfentakisP, VarelaA, ChavdoulaE, SigalaF, SanoudouD, TentaR, GiotiK, KostomitsopoulosN, PapapetropoulosA, TasouliA, FarmakisD, DavosCH, KlinakisA, SuterT, CokkinosDV, IliodromitisEK, WenzelP, and AndreadouI. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose dependent manner: Implications for inotropy. Cardiovasc Res, 116: 576–591, 2020.
FerdinandKC, IzzoJL, LeeJ, MengL, GeorgeJ, SalsaliA, and SemanL. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation, 139: 2098–2109, 2019.
24.
FerranniniE. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab, 26: 27–38, 2017.
25.
FramptonJE. Empagliflozin: a review in type 2 diabetes. Drugs, 78: 1037–1048, 2018.
26.
García-Ropero Á, Vargas-DelgadoAP, Santos-GallegoCG, and BadimonJJ. Inhibition of sodium glucose cotransporters improves cardiac performance. Int J Mol Sci, 20: E3289, 2019.
27.
HabibiJ, AroorAR, SowersJR, JiaG, HaydenMR, GarroM, BarronB, MayouxE, RectorRS, Whaley-ConnellA, and DeMarcoVG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol, 16: 9, 2017.
28.
HausenloyDJ, LecourS, and YellonDM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal, 14: 893–907, 2011.
29.
HawleySA, FordRJ, SmithBK, GowansGJ, ManciniSJ, PittRD, DayEA, SaltIP, SteinbergGR, and HardieDG. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes, 65: 2784–2794, 2016.
30.
HeuschG. Molecular basis of cardioprotection. Circ Res, 116: 674–699, 2015.
31.
Iborra-EgeaO, Santiago-VacasE, YuristaSR, LupónJ, PackerM, HeymansS, ZannadF, ButlerJ, Pascual-FigalD, LaxA, NúñezJ, BoerRA de, and Bayés-GenísA. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. J Am Coll Cardiol Basic Trans Sci, 4: 831–840, 2019.
32.
JespersenNR, LassenTR, HjortbakMV, Støttrup NB and BøtkerHE. Sodium glucose transporter 2 (SGLT2) inhibition does not protect the myocardium from acute ischemic reperfusion injury but modulates postischemic mitochondrial function. Cardiovasc Pharmacol, 6: 210, 2017.
LatosinskaA, MakridakisM, FrantziM, BorràsDM, JanssenB, MullenW, ZoidakisJ, MerseburgerAS, JankowskiV, MischakH, and VlahouA. Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of –omics findings. Sci Rep, 6: 25619, 2016.
35.
LatosinskaA, MokouM, MakridakisM, MullenW, ZoidakisJ, LygirouV, FrantziM, KatafigiotisI, StravodimosK, HupeMC, DobrzynskiM, KolchW, MerseburgerAS, MischakH, RoubelakisMG, and VlahouA. Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention. Oncotarget, 8: 69435–69455, 2017.
36.
LatosinskaA, VougasK, MakridakisM, KleinJ, MullenW, AbbasM, StravodimosK, KatafigiotisI, MerseburgerAS, ZoidakisJ, MischakH, VlahouA, and JankowskiV. Comparative analysis of label-free and 8-Plex iTRAQ approach for quantitative tissue proteomic analysis. PLoS One, 10: e0137048, 2015.
37.
LeePC, GangulyS, and GohS-Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev, 19: 1630–1641, 2018.
38.
LeeT-M, ChangN-C, and LinS-Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med, 104: 298–310, 2017.
39.
LimVG, BellRM, ArjunS, Kolatsi-JoannouM, LongDA, and YellonDM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci, 4: 15–26, 2019.
40.
LubecG and Afjehi-SadatL. Limitations and pitfalls in protein identification by mass spectrometry. Chem Rev, 107: 3568–3584, 2007.
41.
LygirouV, LatosinskaA, MakridakisM, MullenW, DellesC, SchanstraJP, ZoidakisJ, PieskeB, MischakH, and VlahouA. Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. J Transl Med, 16: 104, 2018.
42.
ManciniSJ, BoydD, KatwanOJ, StrembitskaA, AlmabroukTA, KennedyS, PalmerTM, and SaltIP. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep, 8: 5276, 2018.
MengX, BrownJM, AoL, ShamesBD, BanerjeeA, and HarkenAH. Reduction of infarct size in the rat heart by LPS preconditioning is associated with expression of angiogenic growth factors and increased capillary density. Shock, 12: 25–31, 1999.
45.
MetsaluT and ViloJ. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res, 43: W566–W570, 2015.
46.
MokouM, KleinJ, MakridakisM, BitsikaV, BascandsJ-L, Saulnier-BlacheJS, MullenW, SachererM, ZoidakisJ, PieskeB, MischakH, RoubelakisMG, SchanstraJP, and VlahouA. Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease. EBioMedicine, 41: 91–104, 2019.
47.
MotherwellJM, AndersonCR, and MurfeeWL. Endothelial cell phenotypes are maintained during angiogenesis in cultured microvascular networks. Sci Rep, 8: 1–11, 2018.
48.
NealB, PerkovicV, MahaffeyKW, de ZeeuwD, FulcherG, EronduN, ShawW, LawG, DesaiM, and MatthewsDR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 377: 644–657, 2017.
49.
NeuenBL, OhkumaT, NealB, MatthewsDR, de ZeeuwD, MahaffeyKW, FulcherG, DesaiM, LiQ, DengH, RosenthalN, JardineMJ, BakrisG, and PerkovicV. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation, 138: 1537–1550, 2018.
50.
NikolaouP-E, BoenglerK, EfentakisP, VouvogiannopoulouK, ZogaA, Gaboriaud-KolarN, MyrianthopoulosV, AlexakosP, KostomitsopoulosN, RerrasI, Tsantili-KakoulidouA, SkaltsounisAL, PapapetropoulosA, IliodromitisEK, SchulzR, and AndreadouI. Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. Cardiovasc Res, 115: 1228–1243, 2019.
51.
This reference has been deleted.
52.
OelzeM, Kröller-SchönS, WelschofP, JansenT, HausdingM, MikhedY, StammP, MaderM, ZinßiusE, AgdauletovaS, GottschlichA, StevenS, SchulzE, BottariSP, MayouxE, MünzelT, and DaiberA. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One, 9: e112394, 2014.
53.
OlivaRV and BakrisGL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens, 8: 330–339, 2014.
54.
PennaC, PerrelliM-G, and PagliaroP. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal, 18: 556–599, 2012.
55.
PrasadV, LorenzJN, MillerML, VairamaniK, NiemanML, WangY, and ShullGE. Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress. J Mol Cell Cardiol, 65: 33–42, 2013.
56.
SayourAA, Korkmaz-IcözS, LoganathanS, RuppertM, SayourVN, OláhA, BenkeK, BruneM, BenkőR, HorváthEM, KarckM, MerkelyB, RadovitsT, and SzabóG. Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med, 17: 127, 2019.
57.
SchülerR, EfentakisP, WildJ, LagrangeJ, GarlapatiV, MolitorM, KossmannS, OelzeM, StammP, LiH, SchäferK, MünzelT, DaiberA, WaismanA, WenzelP, and KarbachSH. T Cell-derived IL-17A induces vascular dysfunction via perivascular fibrosis formation and dysregulation of ·NO/cGMP signaling. Oxid Med Cell Longev, 2019: 6721531, 2019.
58.
StanleyBA, SivakumaranV, ShiS, McDonaldI, LloydD, WatsonWH, AonMA, and PaolocciN. Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem, 286: 33669–33677, 2011.
TaharaA, TakasuT, YokonoM, ImamuraM, and KurosakiE. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci, 130: 159–169, 2016.
61.
TeramiN, OgawaD, TachibanaH, HatanakaT, WadaJ, NakatsukaA, EguchiJ, HoriguchiCS, NishiiN, YamadaH, TakeiK, and MakinoH. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9: e100777, 2014.
62.
TimmisA, TownsendN, GaleC, GrobbeeR, ManiadakisN, FlatherM, WilkinsE, WrightL, VosR, BaxJ, BlumM, PintoF, and VardasP. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J, 39: 508–579, 2018.
63.
UthmanL, NederlofR, EerbeekO, BaartscheerA, SchumacherC, BuchholtzN, HollmannMW, CoronelR, WeberNC, and ZuurbierCJ. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res, 115: 1533–1545, 2019.
64.
VanAS, BalteauM, GinionA, FertéL, BattaultS, RavensteinCM, BalligandJL, DaskalopoulosEP, GilonP, DespaF, DespaS, VanoverscheldeJL, HormanS, KoepsellH, BerryG, HueL, BertrandL, and BeauloyeC. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep, 7: 41166, 2017.
65.
WangJ, DuncanD, ShiZ, and ZhangB. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res, 41: W77–W83, 2013.
66.
WangJ, VasaikarS, ShiZ, GreerM, and ZhangB. WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res, 45: W130–W137, 2017.
67.
WiviottSD, RazI, BonacaMP, MosenzonO, KatoET, CahnA, SilvermanMG, ZelnikerTA, KuderJF, MurphySA, BhattDL, LeiterLA, McGuireDK, WildingJPH, RuffCT, Gause-NilssonIAM, FredrikssonM, JohanssonPA, LangkildeA-M, SabatineMS;
DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 380: 347–357, 2019.
68.
YeY, JiaX, BajajM, and BirnbaumY. Dapagliflozin attenuates Na+/H+ exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther, 32: 553–558, 2018.
69.
YuristaSR, SilljéHHW, Oberdorf-MaassSU, SchoutenE-M, Pavez GianiMG, HillebrandsJ-L, van GoorH, van VeldhuisenDJ, de BoerRA, and WestenbrinkBD. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail, 21: 862–873, 2019.
70.
ZgheibC, KurdiM, ZoueinFA, GunterBW, StanleyBA, ZgheibJ, RomeroDG, KingSB, PaolocciN, and BoozGW. Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and cardiac myocytes: evidence that STAT3 signaling is redox-sensitive. PLoS One, 7: e43313, 2012.
71.
ZgheibC, ZoueinFA, KurdiM, and BoozGW. Differential STAT3 signaling in the heart. JAKSTAT, 1: 101–110, 2012.
72.
ZhangY, NakanoD, GuanY, HitomiH, UemuraA, MasakiT, KobaraH, SugayaT, and NishiyamaA. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice. Kidney Int, 94: 524–535, 2018.
73.
ZhouH, WangS, ZhuP, HuS, ChenY, and RenJ. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol, 15: 335–346, 2018.
74.
ZinmanB, WannerC, LachinJM, FitchettD, BluhmkiE, HantelS, MattheusM, DevinsT, JohansenOE, WoerleHJ, BroedlUC, and InzucchiSE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 373: 2117–2128, 2015.
75.
ZoueinFA, AltaraR, ChenQ, LesnefskyEJ, KurdiM, and BoozGW. Pivotal Importance of STAT3 in protecting the heart from acute and chronic stress: new advancement and unresolved issues. Front Cardiovasc Med, 2: 36, 2015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
